Tunisian Lung Cancer Study

Dacima Consulting1,334 enrolled

Overview

This is a prospective, multicenter, observational, national study. Eligible patients will be recruited consecutively among subjects with proven lung cancer, including any disease stage withclinical, therapeutic and evolutive discription.

Study Type

OBSERVATIONAL

Enrollment

1,334

Conditions

Pulmonary Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age more than 18 years * Patients receiving health care in the departments of pulmonology, oncology, radiation oncology and thoracic surgery, whose diagnosis is confirmed histologically and/or by cytology, at least 3 months before the inclusion date * Informed consent Exclusion Criteria: * None

Locations (2)

Tunisian Society of Medical Oncology

Aryanah, Tunisia

NOT_YET_RECRUITING

Tunisian Society of Respiratory Diseases and Allergology

Tunis, Tunisia

RECRUITING

Outcomes

Primary Outcomes

Diagnostic delay

Delay to set the pulmonary cancer diagnosis

Time frame: Day 1

Survival

Overall survival

Time frame: 12 months

Relapse

Time to relapse

Time frame: 12 months

Secondary Outcomes

Recommendation Compliance

Compliance to national and international guidance of pulmonary cancer management

Time frame: Day 1

Central Contacts

Soraya Fenniche, MD

CONTACT

+216 98 586 490 soraya.fenniche@yahoo.fr

Nesrine Mejri, MD

CONTACT

+216 97 429 933 nesrinemejriturki2@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.